IBM (IBM) — The Transparent Read
59/100Cautiously Bullish$278.00 · mixed
This is a cautiously bullish setup, and I lean to the upside — but with eyes open. The structural positives (price above both MAs, neutral RSI, a genuinely favorable macro base rate) outweigh the near-term momentum drag from the negative MACD and lingering death cross. The 74% historical hit rate in this macro regime is the strongest single tell here, and the composite score of 59.4 backs it. I read IBM as a 'buy the trend, respect the chop' name: the path higher is intact, but expect choppiness until the MACD turns and the moving averages flip into a golden cross.
IBM key levels
Show Your Work — every point in IBM's score
The score starts at 50, then each signal below adds or subtracts points. No black box.
| Signal | Type | Points |
|---|---|---|
| Above 200-day MA Price is above its 200-day average — long-term trend is up. | technical | +8 |
| Above 50-day MA Trading above the 50-day average — medium-term momentum is positive. | technical | +5 |
| Death cross 50-day average is below the 200-day (death cross). | technical | -4 |
| RSI neutral RSI is 57 — neither overbought nor oversold. | technical | +0.67 |
| MACD negative MACD is below its signal line — momentum is fading. | technical | -5 |
| Macro regime base rate In 38 past periods like today (Rising inflation + Steady Fed), this stock was higher 90d later 74% of the time (median +5.4%). Historically favorable. | macro | +4.74 |
Macro regime base rate
Today's regime: Rising inflation + Steady Fed
In 38 past periods that looked like today, IBM was higher 90 days later 74% of the time (median move 5.4%). Confidence: high.
The read
IBM: Above Both Major Averages, But Momentum Is Quietly Stalling
Bull case. IBM is trading at $278, comfortably above both its 50-day ($252.94) and 200-day ($270.97) moving averages — the long-term trend points up and medium-term momentum is constructive. RSI at 57 sits in healthy neutral territory with room to run before overbought. The macro backdrop is the real kicker: in 38 analogous periods of rising inflation with a steady Fed, IBM was higher 90 days later 74% of the time with a median gain of +5.4% (high confidence). The composite score of 59.4 lands it firmly in cautiously bullish territory, with daylight between price and support at $243.68.
Bear case. The cracks are in the momentum picture. The MACD histogram is negative at -1.53 and sitting below its signal line — a sign that the recent upward push is fading. There's also a death cross in play: the 50-day average remains below the 200-day, a classic caution flag that the medium-term trend hasn't fully aligned with the long-term one. The overall trend is officially 'mixed,' and resistance at $332.46 sits well above current price, so there's no clean catalyst yet to confirm a breakout.
What would change my mind. A daily close below the 50-day MA at $252.94 — and especially below support at $243.68 — would invalidate the bullish thesis and signal the mixed trend has rolled over to the downside. On the flip side, the MACD histogram crossing back above zero would confirm momentum is re-engaging and strengthen the case toward resistance at $332.46.
IBM — frequently asked
Is IBM a buy according to Tallyread?
Tallyread does not give buy or sell recommendations. It shows a transparent 59/100 read for IBM (IBM), conditioned on today's macro regime, with every scoring input itemized so you can judge for yourself. This is not financial advice.
How is IBM's Tallyread score calculated?
The 59/100 score starts at 50, then adds and subtracts named technical and macro signals — each shown with its point value and a one-line reason in the "Show Your Work" table on this page. Nothing is hidden in a black box.
How does today's Fed-and-inflation regime affect IBM?
In 38 past periods whose macro regime matched today's (Rising inflation + Steady Fed), IBM was higher 90 days later 74% of the time, with a median move of 5.4%. Confidence: high.
Want a fresh read on IBM with the live chart and macro tape?
Run a live IBM read →Last analyzed 2026-06-30 · Data source: tiingo. See the public scorecard and methodology.
This is a historical and technical read for informational and educational purposes only — not financial advice, and not a recommendation to buy or sell IBM. Markets are uncertain; do your own research.